1
|
Kim S, Ho Lee J, Jarusiewicz J, Wang J, Woon Jung K. Hydrogen‐Deuterium Isotope Exchange of Methane via Non‐redox Palladium Catalysis. Eur J Inorg Chem 2022. [DOI: 10.1002/ejic.202200615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Sungah Kim
- Loker Hydrocarbon Research Institute and Department of Chemistry University of Southern California Los Angeles USA
| | - Joo Ho Lee
- Loker Hydrocarbon Research Institute and Department of Chemistry University of Southern California Los Angeles USA
| | - Jamie Jarusiewicz
- Loker Hydrocarbon Research Institute and Department of Chemistry University of Southern California Los Angeles USA
| | - Jen‐Chieh Wang
- Loker Hydrocarbon Research Institute and Department of Chemistry University of Southern California Los Angeles USA
| | - Kyung Woon Jung
- Loker Hydrocarbon Research Institute and Department of Chemistry University of Southern California Los Angeles USA
| |
Collapse
|
2
|
Hu J, Jarusiewicz J, Du G, Nishiguchi G, Yoshimura S, Panetta JC, Li Z, Min J, Yang L, Chepyala D, Actis M, Reyes N, Smart B, Pui CH, Teachey DT, Rankovic Z, Yang JJ. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia. Sci Transl Med 2022; 14:eabo5228. [PMID: 36001679 PMCID: PMC9730446 DOI: 10.1126/scitranslmed.abo5228] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and there is an unmet need for targeted therapies, especially for patients with relapsed disease. We have recently identified pre-T cell receptor and lymphocyte-specific protein tyrosine kinase (LCK) signaling as a common therapeutic vulnerability in T-ALL. LCK inhibitor dasatinib showed efficacy against T-ALL in preclinical studies and in patients with T-ALL; however, this is transient in most cases. Leveraging the proteolysis targeting chimera (PROTAC) approach, we developed a series of LCK degraders using dasatinib as an LCK ligand and phenyl-glutarimide as a cereblon-directing moiety. Our lead compound SJ11646 exhibited marked efficiency in cereblon-mediated LCK degradation in T-ALL cells. Relative to dasatinib, SJ11646 showed up to three orders of magnitude higher cytotoxicity in LCK-activated T-ALL cell lines and primary leukemia samples in vitro, with drastically prolonged suppression of LCK signaling. In vivo pharmacokinetic and pharmacodynamic profiling indicated a 630% increase in the duration of LCK suppression by SJ11646 over dasatinib in patient-derived xenograft models of T-ALL, which translated into its extended leukemia-free survival over dasatinib in vivo. Last, SJ11646 retained a high binding affinity to 51 human kinases, particularly ABL1, KIT, and DDR1, all of which are known drug targets in other cancers. Together, our dasatinib-based phenyl-glutarimide PROTACs are promising therapeutic agents in T-ALL and valuable tools for developing degradation-based therapeutics for other cancers.
Collapse
Affiliation(s)
- Jianzhong Hu
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - Jamie Jarusiewicz
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA
| | - Guoqing Du
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - Gisele Nishiguchi
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA
| | - Satoshi Yoshimura
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - John C. Panetta
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - Zhenhua Li
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - Jaeki Min
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA
| | - Lei Yang
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA
| | - Divyabharathi Chepyala
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA
| | - Marisa Actis
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA
| | - Noemi Reyes
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - Brandon Smart
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - Ching-Hon Pui
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA
| | - David T. Teachey
- Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
| | - Zoran Rankovic
- Department of Chemical Biology & Therapeutics, St. Jude Children’s Research Hospital; Memphis, TN, 38105, USA,,Correspondence to: Jun J. Yang Ph.D., Member, Department of Pharmacy and Pharmaceutical Sciences, Department of Oncology, ; Zoran Rankovic Ph.D., Director, CBT Chemistry Centers, Department of Chemical Biology & Therapeutics, ; St. Jude Children’s Research Hospital, 262 Danny Thomas Pl., Memphis, TN 38105
| | - Jun J. Yang
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA,,Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, 38105, USA,,Correspondence to: Jun J. Yang Ph.D., Member, Department of Pharmacy and Pharmaceutical Sciences, Department of Oncology, ; Zoran Rankovic Ph.D., Director, CBT Chemistry Centers, Department of Chemical Biology & Therapeutics, ; St. Jude Children’s Research Hospital, 262 Danny Thomas Pl., Memphis, TN 38105
| |
Collapse
|
3
|
Hu J, Jarusiewicz J, Min J, Yang L, Chepyala D, Actis M, Du G, Smart B, Maxwell D, Xie B, Yoshimura S, Peng J, Teachey DT, Rankovic Z, Yang JJ. Abstract 423: Induced proximity and proteolytic targeting of LCK as a novel therapeutic approach in T-cell leukemia. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer, with a particularly dismal prognosis in patients with relapsed diseases. Our group recently discovered LCK dependency as a therapeutic vulnerability in 33% of T-ALL and LCK inhibitor dasatinib exhibited strong efficacy in vitro and in vivo (Nat Cancer 2, 284, 2021). However, the transient LCK inhibition by dasatinib resulted in only partial responses, and novel agents are needed to suppress LCK signaling in T-ALL in a sustained fashion to achieve long-term efficacy. We synthesized a set of proteolytic targeting chimeras (PROTACs) that bring LCK to cereblon (CRBN) E3 ligase for ubiquitination and degradation. LCK-PROTACs showed extremely high anti-leukemia sensitivity, i.e., up to 1,561.3 fold increase over dasatinib in LCK-activated T-ALL cell line. Complete LCK degradation was induced by most LCK-PROTACs. Based on solubility, permeability, stability, and anti-leukemia effects in vitro, we prioritized SJ001011646 for further evaluations. SJ001011646 induced 50% LCK degradation at the concentration at ~0.001nM, with superior cytotoxic effects in patient-derived primary T-ALL samples compared to dasatinib. In addition, we confirmed the formation of ternary complex of LCK, SJ001011646, and CRBN, using the AlphaLISA assay. In a wash-out experiment, LCK-dependent T-ALL cells were exposed to SJ001011646 or dasatinib for 18 hours and then monitored for viability recovery. Both dasatinib and SJ001011646 led to dramatic growth inhibition within 2 days. While dasatinib-treated cells started to recover 96 hours after drug removal, cells treated with SJ001011646 failed to recover even after 240 hours. To systematically identify therapeutic targets of SJ001011646, we performed proteomic profiling of T-ALL cells before and after drug treatment in vitro. Overall, 126,670 unique peptides were identified and mapped to 10,158 proteins, of which LCK was most significantly reduced by PROTAC. In parallel, kinome-binding profiling confirmed LCK as a primary target of SJ001011646. Finally, we explored pharmacokinetic and pharmacodynamic properties of SJ001011646 in vivo, using patient-derived xenograft models of T-ALL. Given at the same dosage level as a single injection, SJ001011646 showed 367% increase in the duration of LCK suppression compared to dasatinib. Taken together, we described the development and preclinical evaluation of LCK-targeting PROTACs in T-ALL. Inducing proximity to CRBN and therefore degradation, these agents can produce sustained LCK suppression with much improved anti-leukemia efficacy than small molecule inhibitors, and are therefore promising novel therapeutic agents in T-ALL.
Citation Format: Jianzhong Hu, Jamie Jarusiewicz, Jaeki Min, Lei Yang, Divyabharathi Chepyala, Marisa Actis, Guoqing Du, Brandon Smart, Dylan Maxwell, Boer Xie, Satoshi Yoshimura, Junming Peng, David T. Teachey, Zoran Rankovic, Jun J. Yang. Induced proximity and proteolytic targeting of LCK as a novel therapeutic approach in T-cell leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 423.
Collapse
Affiliation(s)
- Jianzhong Hu
- 1St. Jude Children's Research Hospital, Memphis, TN
| | | | - Jaeki Min
- 1St. Jude Children's Research Hospital, Memphis, TN
| | - Lei Yang
- 1St. Jude Children's Research Hospital, Memphis, TN
| | | | - Marisa Actis
- 1St. Jude Children's Research Hospital, Memphis, TN
| | - Guoqing Du
- 1St. Jude Children's Research Hospital, Memphis, TN
| | | | | | - Boer Xie
- 1St. Jude Children's Research Hospital, Memphis, TN
| | | | - Junming Peng
- 1St. Jude Children's Research Hospital, Memphis, TN
| | | | | | - Jun J. Yang
- 1St. Jude Children's Research Hospital, Memphis, TN
| |
Collapse
|
4
|
Min J, Mayasundari A, Keramatnia F, Jonchere B, Yang SW, Jarusiewicz J, Actis M, Das S, Young B, Slavish J, Yang L, Li Y, Fu X, Garrett SH, Yun M, Li Z, Nithianantham S, Chai S, Chen T, Shelat A, Lee RE, Nishiguchi G, White SW, Roussel MF, Potts PR, Fischer M, Rankovic Z. Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202108848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Jaeki Min
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Anand Mayasundari
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Fatemeh Keramatnia
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Barbara Jonchere
- Department of Tumor Cell Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Seung Wook Yang
- Department of Cell & Molecular Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Jamie Jarusiewicz
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Marisa Actis
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Sourav Das
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Brandon Young
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Jake Slavish
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Lei Yang
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Yong Li
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Xiang Fu
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Shalandus H. Garrett
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Mi‐Kyung Yun
- Department of Structural Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Zhenmei Li
- Department of Structural Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Stanley Nithianantham
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Sergio Chai
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Taosheng Chen
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Anang Shelat
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Richard E. Lee
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Gisele Nishiguchi
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Stephen W. White
- Department of Structural Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Martine F. Roussel
- Department of Tumor Cell Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Patrick Ryan Potts
- Department of Cell & Molecular Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Marcus Fischer
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
- Department of Structural Biology St. Jude Children's Research Hospital Memphis TN 38105 USA
| | - Zoran Rankovic
- Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis TN 38105 USA
| |
Collapse
|
5
|
Min J, Mayasundari A, Keramatnia F, Jonchere B, Yang SW, Jarusiewicz J, Actis M, Das S, Young B, Slavish J, Yang L, Li Y, Fu X, Garrett SH, Yun MK, Li Z, Nithianantham S, Chai S, Chen T, Shelat A, Lee RE, Nishiguchi G, White SW, Roussel MF, Potts PR, Fischer M, Rankovic Z. Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angew Chem Int Ed Engl 2021; 60:26663-26670. [PMID: 34614283 PMCID: PMC8648984 DOI: 10.1002/anie.202108848] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Indexed: 12/15/2022]
Abstract
Targeting cereblon (CRBN) is currently one of the most frequently reported proteolysis-targeting chimera (PROTAC) approaches, owing to favorable drug-like properties of CRBN ligands, immunomodulatory imide drugs (IMiDs). However, IMiDs are known to be inherently unstable, readily undergoing hydrolysis in body fluids. Here we show that IMiDs and IMiD-based PROTACs rapidly hydrolyze in commonly utilized cell media, which significantly affects their cell efficacy. We designed novel CRBN binders, phenyl glutarimide (PG) analogues, and showed that they retained affinity for CRBN with high ligand efficiency (LE >0.48) and displayed improved chemical stability. Our efforts led to the discovery of PG PROTAC 4 c (SJ995973), a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins that inhibited the viability of human acute myeloid leukemia MV4-11 cells at low picomolar concentrations (IC50 =3 pM; BRD4 DC50 =0.87 nM). These findings strongly support the utility of PG derivatives in the design of CRBN-directed PROTACs.
Collapse
Affiliation(s)
- Jaeki Min
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Anand Mayasundari
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Fatemeh Keramatnia
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Barbara Jonchere
- Department of Tumor Cell Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Seung Wook Yang
- Department of Cell & Molecular Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Jamie Jarusiewicz
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Marisa Actis
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Sourav Das
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Brandon Young
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Jake Slavish
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Lei Yang
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Yong Li
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Xiang Fu
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Shalandus H. Garrett
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Mi-Kyung Yun
- Department of Structural Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Zhenmei Li
- Department of Structural Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Stanley Nithianantham
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Sergio Chai
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Taosheng Chen
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Anang Shelat
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Richard E. Lee
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Gisele Nishiguchi
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Stephen W. White
- Department of Structural Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Martine F. Roussel
- Department of Tumor Cell Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Patrick Ryan Potts
- Department of Cell & Molecular Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Marcus Fischer
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
- Department of Structural Biology, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| | - Zoran Rankovic
- Department of Chemical Biology and Therapeutics, St. Jude
Children’s Research Hospital, Memphis, Tennessee 38105, United States
| |
Collapse
|
6
|
Jarusiewicz J, Choe Y, Yoo KS, Park CP, Jung KW. Efficient three-component Strecker reaction of aldehydes/ketones via NHC-amidate palladium(II) complex catalysis. J Org Chem 2009; 74:2873-6. [PMID: 19265413 PMCID: PMC2713785 DOI: 10.1021/jo900163w] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A simple and efficient one-pot, three-component method has been developed for the synthesis of alpha-aminonitriles. This Strecker reaction is applicable for aldehydes and ketones with aliphatic or aromatic amines and trimethylsilyl cyanide in the presence of a palladium Lewis acid catalyst in dichloromethane solvent at room temperature.
Collapse
Affiliation(s)
- Jamie Jarusiewicz
- Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, Los Angeles, California 90089-0166, USA
| | - Yvonne Choe
- Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, Los Angeles, California 90089-0166, USA
| | - Kyung Soo Yoo
- Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, Los Angeles, California 90089-0166, USA
| | - Chan Pil Park
- Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, Los Angeles, California 90089-0166, USA
| | - Kyung Woon Jung
- Loker Hydrocarbon Research Institute and Department of Chemistry, University of Southern California, Los Angeles, California 90089-0166, USA
| |
Collapse
|
7
|
Jung K, Jarusiewicz J, Yoo K. Highly Regioselective Heck Coupling Reactions of Aryl Halides and Dihydropyran in the Presence of an NHC-Pyridine Ligand. Synlett 2009. [DOI: 10.1055/s-0028-1087528] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Jarusiewicz J, Sherma J, Fried B. Separation of Sterols by Reversed Phase and Argentation Thin Layer Chromatography. Their Identification in Snail Bodies. J LIQ CHROMATOGR R T 2007. [DOI: 10.1080/10826070500189869] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Jamie Jarusiewicz
- a Department of Chemistry , Lafayette College , Easton, Pennsylvania, USA
| | - Joseph Sherma
- a Department of Chemistry , Lafayette College , Easton, Pennsylvania, USA
| | - Bernard Fried
- b Department of Biology , Lafayette College , Easton, Pennsylvania, USA
| |
Collapse
|
9
|
Jarusiewicz J, Fried B, Sherma J. High-performance thin-layer chromatographic analysis of neutral lipids and phospholipids in the apple snailPomacea bridgesii. JPC-J PLANAR CHROMAT 2004. [DOI: 10.1556/jpc.17.2004.6.11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|